Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -31.75% is in line with its 5-year average of -29.29%, around the middle of its 5-year range (-37.50%–-19.49%).
6.62% above its 12-month average of -34.00%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -3.54%.
RETURN ON ASSETS (ROA)
-31.75%
RETURN ON ASSETS (ROA) AVG TTM
-34.00%
RETURN ON ASSETS (ROA) AVG 3Y
-32.33%
RETURN ON ASSETS (ROA) AVG 5Y
-29.29%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+6.62%
CURRENT VS 3Y AVG
+1.79%
CURRENT VS 5Y AVG
-8.41%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+1.60%
vs the sector median at left
Foghorn Therapeutics Inc.
Market Cap
$115.67M
Return on Assets (ROA)
-31.75%
TTM Avg
-34.00%
3Y Avg
-32.33%
5Y Avg
-29.29%
Market Cap
$116.76M
Return on Assets (ROA)
-19.30%
TTM Avg
-19.59%
3Y Avg
-15.38%
5Y Avg
-15.18%
Market Cap
$114.46M
Return on Assets (ROA)
-134.18%
TTM Avg
-145.83%
3Y Avg
-164.39%
5Y Avg
-180.40%
Market Cap
$113.89M
Return on Assets (ROA)
-128.96%
TTM Avg
-127.49%
3Y Avg
-112.64%
5Y Avg
-129.28%
Market Cap
$113.77M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
Market Cap
$117.76M
Return on Assets (ROA)
-49.93%
TTM Avg
-95.40%
3Y Avg
-72.70%
5Y Avg
-57.07%
Market Cap
$112.94M
Return on Assets (ROA)
-48.90%
TTM Avg
-85.01%
3Y Avg
-256.52%
5Y Avg
-384.82%
Market Cap
$118.59M
Return on Assets (ROA)
-110.24%
TTM Avg
-77.16%
3Y Avg
-67.85%
5Y Avg
-53.38%
Market Cap
$112.57M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Foghorn Therapeutics Inc. (FHTX) | $115.67M | -31.75% | -34.00% | -32.33% | -29.29% |
| MaxCyte, Inc. (MXCT)vs › | $116.76M | -19.30% | -19.59% | -15.38% | -15.18% |
| Lucid Diagnostics Inc. (LUCD)vs › | $114.46M | -134.18% | -145.83% | -164.39% | -180.40% |
| Genelux Corporation (GNLX)vs › | $113.89M | -128.96% | -127.49% | -112.64% | -129.28% |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -0.05% | -38.03% | -60.31% | -59.32% |
| Spruce Biosciences, Inc. (SPRB)vs › | $117.76M | -49.93% | -95.40% | -72.70% | -57.07% |
| Unicycive Therapeutics, Inc. (UNCY)vs › | $112.94M | -48.90% | -85.01% | -256.52% | -384.82% |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | -110.24% | -77.16% | -67.85% | -53.38% |
| Caribou Biosciences, Inc. (CRBU)vs › | $112.57M | -72.42% | -66.03% | -45.57% | -48.77% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | -53.26% | -24.98% | -43.10% | -143.56% |
ROA
-31.8%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.50% |
| 2024-12-31 | -30.50% |
| 2023-12-31 | -34.42% |
| 2022-12-31 | -26.89% |
| 2021-12-31 | -19.49% |
| 2020-12-31 | -26.92% |
| 2019-12-31 | -228.84% |
| 2018-12-31 | -61.17% |
